Browsing Tag
Prader–Willi syndrome
2 posts
Rhythm Pharmaceuticals (RYTM) TRANSCEND trial in NEJM shows 19.8% placebo-adjusted BMI reduction
Rhythm Pharma (RYTM) TRANSCEND Phase 3 published in NEJM validates IMCIVREE for acquired hypothalamic obesity. 10,000-patient US market launch trajectory ahead.
Levo gets FDA fast track status for LV-101 in Prader-Willi syndrome
US biotech company Levo Therapeutics has been granted fast track designation for LV-101 (intranasal carbetocin) from the US…